EUVIMEDEUVIMED entdecken
Crossref

Overexpression of the erythropoietin receptor is associated with upregulation of tubulin beta 6 and paclitaxel resistance in ovarian adenocarcinoma cells

Pavol Harvanik, Kristína Danková, Zuzana Solárová, Martina Šemeláková, Mangesh Bhide, Peter Solár

Acta Chimica Slovenica · 20.03.2026 · 73 (1) · 258-266

DOI: 10.17344/acsi.2025.9420 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Chimica Slovenica, online erschienen am 20.03.2026. Verfasst von Pavol Harvanik und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biology, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, SK-04154 Košice, Slovak Republic. Hauptthemen laut MEDLINE: Paclitaxel, Tubulin, Ovarian Neoplasms, Drug Resistance, Neoplasm.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The emergence of tumor cell resistance is one of the major issues in current oncology practice. It reduces the effectiveness of therapy and worsens cancer patients’ prognoses. However, it confirms a wide range of molecular interactions as well as the complexity of the human organism. Our previous research confirmed the functionality of the erythropoietin receptor (EPOR) in ovarian and breast cancer cells, as well as its relationship to these cells’ sensitivity to specific therapies. The current study demonstrates that EPOR overexpression in human ovarian adenocarcinoma cells A2780 is directly linked to paclitaxel resistance. Furthermore, EPOR overexpression results in morphological changes that vary according to the pattern of EPOR isotypes expressed. In this regard, the most interesting result appears to be the change in the shape of the T clone, which has a tendency to form spheroidal structures. In addition, functional enrichment analysis demonstrated that EPOR-associated differentially expressed genes are involved in several biological and cell processes. Indeed, a T clone with a single 68 kDa EPOR isotype demonstrates significant resistance to paclitaxel therapy and is associated with the upregulation of tubulin beta 6.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelTubulinOvarian NeoplasmsDrug Resistance, NeoplasmUp-RegulationAdenocarcinomaReceptors, ErythropoietinAntineoplastic Agents, PhytogenicHumansFemaleCell Line, Tumor

Substanzen

PaclitaxelTubulinReceptors, ErythropoietinAntineoplastic Agents, Phytogenic

Autor:innen und Institutionen

  • Department of Medical Biology, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, SK-04154 Košice, Slovak Republic.
  • Department of Pharmacology, Faculty of Medicine, Pavol Jozef Šafárik University in Košice, SK-04154 Košice, Slovak Republic.
  • Laboratory of Biomedical Microbiology and Immunology, University of Veterinary Medicine and Pharmacy in Košice, SK-04154 Košice, Slovak Republic; Institute of Neuroimmunology, Slovak Academy of Sciences, Dubravska cesta…

Zitieren

APA

Harvanik, P., Danková, K., Solárová, Z., Šemeláková, M., Bhide, M., & Solár, P. (2026). Overexpression of the erythropoietin receptor is associated with upregulation of tubulin beta 6 and paclitaxel resistance in ovarian adenocarcinoma cells. Acta Chimica Slovenica, 73(1), 258-266. https://doi.org/10.17344/acsi.2025.9420

Vancouver

Harvanik P, Danková K, Solárová Z, Šemeláková M, Bhide M, Solár P. Overexpression of the erythropoietin receptor is associated with upregulation of tubulin beta 6 and paclitaxel resistance in ovarian adenocarcinoma cells. Acta Chimica Slovenica. 2026;73(1):258-266. doi:10.17344/acsi.2025.9420

BibTeX
@article{Harvanik2026,
  author = {Harvanik, Pavol and Danková, Kristína and Solárová, Zuzana and Šemeláková, Martina and Bhide, Mangesh and Solár, Peter},
  title = {Overexpression of the erythropoietin receptor is associated with upregulation of tubulin beta 6 and paclitaxel resistance in ovarian adenocarcinoma cells},
  journal = {Acta Chimica Slovenica},
  year = {2026},
  volume = {73},
  number = {1},
  pages = {258--266},
  doi = {10.17344/acsi.2025.9420}
}
Kostenlos starten →